
    
      This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel group
      study. After appropriate screening, approximately 180 male and female patients from up to 33
      study centers will be treated in this study. Patients with type 2 diabetes mellitus who are
      being treated by diet, exercise, untreated with antidiabetic medications or treated with and
      metformin monotherapy or in combination with one other antidiabetic drug (excluding insulin)
      are eligible for enrollment.
    
  